Every 8-K that AEON Biopharma, Inc. (AEON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AEON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEON filings page.
AEON Biopharma, Inc. reported second quarter 2026 results and a corporate update focused on advancing ABP-450, its proposed biosimilar to BOTOX for therapeutic indications. The company highlighted FDA-regulatory progress, including a Biosimilar Biological Product Development (BPD) Type 2a meeting where the FDA reviewed its analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback that supports AEON’s planned analytical development approach.
AEON completed a $15.3 million underwritten public financing in July 2026, generating approximately $13.6 million in net upfront proceeds and milestone warrants that could provide up to an additional $34.0 million in gross proceeds upon full cash exercise. The company reported cash and cash equivalents of $3.4 million as of June 30, 2026, and expects, including the July proceeds, to fund operations into the first quarter of 2027.
For the quarter ended June 30, 2026, AEON recorded a loss from operations of $5.9 million and a net loss of $1.2 million, with results influenced by non-cash fair value changes in convertible notes and warrant liabilities. Total liabilities were $21.3 million and stockholders’ deficit was $15.4 million as of June 30, 2026. The company also disclosed that it regained full NYSE American continued listing compliance on August 3, 2026.
AEON Biopharma, Inc. reports that it has regained compliance with NYSE American’s continued listing standards. NYSE Regulation confirmed that previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide have been resolved, so the “.BC” below-compliance indicator is expected to be removed and the company taken off NYSE American’s noncompliant issuers list, while it remains subject to ongoing listing standards.
The company regained compliance following completion of an underwritten public offering closed on July 15, 2026, involving 17,851,599 shares of Class A common stock and pre-funded warrants to purchase 24,837,008 shares, plus an additional 4,696,102 shares sold on July 23, 2026 through a partial over-allotment exercise. AEON received approximately $13.6 million in net proceeds and has the potential to receive up to $34.0 million in additional gross proceeds upon full cash exercise of milestone warrants. AEON believes its stockholders’ equity now exceeds the $4.0 million minimum required under Section 1003(a)(ii), although its June 30, 2026 balance sheet in the upcoming Form 10-Q will still show a stockholders’ deficit and reflect the offering as a subsequent event.
AEON Biopharma, Inc. reports that on July 23, 2026 it issued 4,696,102 additional shares of Class A common stock to the underwriters in its recent public offering, following the representative’s partial exercise of an over-allotment option under an underwriting agreement.
The transaction generated approximately $1.5 million in gross proceeds and approximately $1.4 million in net proceeds after underwriting discounts and commissions. The representative had previously exercised in full the over-allotment portion relating to the two-year and five-year milestone warrants, each covering 6,403,290 shares of common stock or pre-funded warrants in lieu thereof.
AEON Biopharma entered into an underwriting agreement for an underwritten public offering of 42,688,606 shares of Class A common stock (or pre-funded warrants in lieu), with each unit accompanied by one two-year and one five-year milestone warrant. The combined public offering price is $0.3221 per share of common stock (or $0.3220 per pre-funded warrant) and accompanying milestone warrants. The representative also received a 30-day over-allotment option that included additional milestone warrants, which was exercised for 6,403,290 two-year and 6,403,290 five-year milestone warrants.
The offering, which closed on July 15, 2026, is expected to generate approximately $13.75 million in gross proceeds and provided net proceeds of about $12.2 million. If all milestone warrants are exercised in cash, AEON could receive up to an additional $29.6 million. Pre-funded warrants are immediately exercisable at $0.0001 per share with no expiration, subject to 4.99% or 9.99% beneficial ownership caps, adjustable up to 19.99%. Two-year milestone warrants are exercisable at $0.3221 per share and five-year milestone warrants at $0.3704 per share, with expirations tied to fixed anniversaries or specified FDA and clinical milestones for ABP-450. AEON plans to use proceeds for working capital and general corporate purposes, including comparative analytical testing on ABP-450 to support biosimilarity to BOTOX®, and agreed to 90-day issuance and lock-up restrictions and a 180-day ban on variable rate transactions.
AEON Biopharma, Inc. reported results from its Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected Marc Forth and Seongsoo Park as Class III directors to terms ending at the 2029 annual meeting, with 13,297,322 and 13,117,299 votes "for," respectively.
Stockholders also ratified the appointment of KPMG LLP as AEON Biopharma’s independent registered public accounting firm for the fiscal year ended December 31, 2026, with 21,502,418 votes "for," 18,217 "against" and 1,498 "abstain."
AEON Biopharma, Inc. furnished a new corporate investor presentation on its website and via an exhibit to a current report. The presentation, dated May 2026 and labeled as Exhibit 99.1, may be used by management in future meetings to discuss the company.
The company states that the presentation includes a slide titled “Forward-Looking Statements” for important cautionary information. AEON also clarifies that the materials furnished under Item 7.01, including Exhibit 99.1, are not deemed filed under the securities laws and are not automatically incorporated into other SEC filings.
AEON Biopharma reported first-quarter 2026 results and a corporate update focused on its ABP-450 biosimilar program and balance sheet. The company recorded a net loss of $11.8 million for the quarter, compared with net income of $9.1 million in the prior-year period, largely driven by fair value changes in financial instruments.
Operating expenses rose as selling, general and administrative costs reached $3.9 million and research and development spending was $2.0 million. AEON ended March 31, 2026 with cash and cash equivalents of $6.2 million, and stated that, including $0.9 million of April ATM proceeds, this is expected to fund operations into the third quarter of 2026.
The company highlighted positive FDA feedback from a BPD Type 2a meeting supporting ABP-450’s analytical similarity strategy under the 351(k) biosimilar pathway. AEON also completed a $6 million PIPE financing and a Daewoong note exchange, which together reduced outstanding debt by more than 90% and contributed to shrinking total stockholders’ deficit from $(55.0) million to $(16.8) million.
AEON Biopharma, Inc. reported that NYSE American sent an additional notice stating the company no longer meets an extra continued listing standard. The exchange requires stockholders’ equity of at least $4.0 million when a company has losses in three of its four most recent fiscal years.
AEON instead reported a stockholders’ deficit of approximately $55 million as of December 31, 2025, along with losses in three of its four most recent fiscal years. The company is already operating under a previously accepted plan to regain compliance by August 3, 2026.
The new notice does not immediately affect trading of AEON’s Class A common stock, which will continue to list on NYSE American with a “.BC” below‑compliance indicator and inclusion on the noncompliant issuers list. If AEON fails to regain compliance by August 3, 2026, NYSE American may begin delisting proceedings, which AEON would have the right to appeal.
AEON Biopharma reported a sharp swing to loss for 2025 while advancing its ABP-450 biosimilar program and repairing its balance sheet. For the year ended December 31, 2025, net loss was $39,222 thousand, compared with net income of $42,005 thousand in 2024, driven largely by volatile fair value and warrant-related items.
Total operating costs and expenses were $12,803 thousand, versus $(72,985) thousand in 2024, when a large non-cash reduction in contingent consideration had boosted results. AEON ended 2025 with cash and cash equivalents of $3,006 thousand, total liabilities of $60,587 thousand, and a stockholders’ deficit of $55,027 thousand, highlighting a highly leveraged capital structure.
Strategically, the company reported positive initial analytical biosimilarity data for ABP-450 versus BOTOX, a favorable FDA BPD Type 2a meeting outlining a clear analytical path, and a $6 million PIPE financing and Daewoong note exchange that reduced outstanding debt by more than 90%.
AEON Biopharma appointed John Bencich as Chief Financial Officer effective March 9, 2026, and principal financial officer effective April 1, 2026, as part of a plan to strengthen its leadership during key regulatory and financing milestones. He brings more than 25 years of biotechnology and life sciences finance experience, including prior CEO, COO and CFO roles at several public and private companies.
His employment agreement provides a $450,000 base salary, a 40% target cash bonus opportunity, severance protections, and equity inducement grants of 754,717 restricted stock units and 235,849 performance-based restricted stock units under AEON’s 2025 Employment Inducement Incentive Award Plan. AEON also entered into a new employment agreement with Chief Accounting Officer Jennifer Sy, maintaining her existing pay and bonus targets while formalizing severance and change-in-control protections. The Board amended the Inducement Plan to reserve an additional 1,000,000 shares of Class A common stock for future equity awards.
AEON Biopharma completed an exchange of its senior secured convertible notes held by Daewoong for a mix of equity and new securities. In full satisfaction of the old notes, AEON issued 11,918,380 shares of common stock, 11,236,631 pre-funded warrants, a new senior secured convertible note with a principal amount of $1,500,000, and warrants to buy up to 8,000,000 shares at $1.09392 per share. After this exchange, 24,024,282 common shares were outstanding as of January 21, 2026.
Stockholders approved a PIPE financing proposal authorizing 4,616,924 shares (or pre-funded warrants), 6,581,829 warrants and shares issuable under True-Up Warrants, as well as an amended 2023 incentive plan and the Daewoong note exchange. AEON and Daewoong also amended their license so that a termination purchase right will expire once Daewoong sells 50% of its AEON common stock. A second closing of the previously agreed private placement is expected in the week of January 26, 2026, adding more shares and warrants under the approved PIPE structure.
AEON Biopharma, Inc. released an updated corporate investor presentation and posted it in the investor relations section of its website. The presentation, dated January 2026, is also furnished as Exhibit 99.1 and may be used by company management in future meetings about the business.
The company highlights that the presentation contains forward-looking statements and directs readers to a specific “Forward-Looking Statements” slide for important cautionary information. This disclosure is furnished under Regulation FD and is explicitly not treated as filed for liability purposes or automatically incorporated into other securities law documents unless specifically referenced.
AEON Biopharma entered into an Exchange Agreement with Daewoong to swap Daewoong’s existing senior secured convertible notes into equity and a new $1.5 million senior secured convertible note, plus warrants. The company estimates the exchange will result in approximately 23.1 million newly issued shares of common stock or pre-funded warrants, based on principal and accrued interest, with Daewoong’s ownership capped at 49.99%.
Daewoong will also receive warrants to purchase up to 8,000,000 shares of common stock at an exercise price of $1.09392 per share, exercisable in cash for five years after issuance. The New Convertible Note bears interest at 15.79% annually, matures on April 12, 2030, cannot be prepaid, and is secured by a first‑priority lien on substantially all assets of AEON Biopharma and its subsidiary.
The note can automatically convert at a 1.3x factor into equity upon a qualified equity financing of at least $30.0 million, and Daewoong has an additional conversion option tied to a Biologics License Application submission for ABP‑450 or a Change of Control. The exchange requires stockholder approval under NYSE American rules, and AEON plans to nominate a Daewoong designee, currently director Seongsoo Park, for a Class III board seat at the 2026 annual meeting.
AEON Biopharma, Inc. furnished a new investor Corporate Presentation under Regulation FD. The presentation, dated December 2025, has been made available in the investor relations section of AEON’s website and is also filed as Exhibit 99.1 to this report. Management may use the same materials in future meetings to explain the company’s business and outlook.
The company notes that the Corporate Presentation contains forward-looking statements and directs readers to the slide titled “Forward-Looking Statements” for important cautionary information. The materials provided in this report, including Exhibit 99.1, are being furnished rather than filed, meaning they are not automatically subject to certain liability provisions or incorporated into other securities law filings unless specifically referenced.
AEON Biopharma furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company issued a press release with details, which is included as Exhibit 99.1 to this report.
The information in this update (including Exhibit 99.1) is furnished, not filed, under the Exchange Act. AEON’s Class A common stock trades on the NYSE American under the symbol AEON.
AEON Biopharma announced a private placement and a binding note exchange term sheet. The company agreed to sell equity and warrants at a purchase price of $0.9116 per Share (or $0.9115 per pre‑funded warrant). The first closing is expected the week of November 17, 2025, with 1,964,905 Shares (or pre‑funded warrants) to be issued.
The second closing, subject to stockholder approval and consummation of the Daewoong exchange, is expected to include 4,616,924 Shares (or pre‑funded warrants) and 6,581,829 Warrants. The Warrants are cash‑exercise only at $1.09392 per share and are exercisable for five years from the second closing; pre‑funded and true‑up warrants have a $0.0001 exercise price. Warrants include full‑ratchet anti‑dilution with a floor of $0.30387, and exercises are limited by a 9.99% beneficial ownership cap (electable up to 19.99% with notice).
AEON and Daewoong signed a binding term sheet to exchange Daewoong’s existing notes for a $1.5 million note due 2030, an estimated 23,103,694 Exchange Shares (assumes a January 15, 2026 vote), and 8,000,000 Warrants at $1.09392. AEON also agreed to file a resale registration statement within 20 days of the earlier of the second closing or a specified termination.
AEON Biopharma, Inc. furnished an investor presentation as part of a corporate update. On September 8, 2025, the company made a “Corporate Presentation” available in the investor relations section of its website and attached it as Exhibit 99.1. Management may use this presentation in future meetings to discuss the company. The materials include a slide on forward-looking statements that outlines important cautionary information. The presentation and related information are furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
AEON Biopharma, Inc. furnished an update on its business by announcing financial results for the second quarter ended June 30, 2025. The company disclosed that these results were communicated through a press release dated August 12, 2025, which is included as Exhibit 99.1 to this Form 8-K.
The press release is treated as "furnished" rather than "filed" under the securities laws, which means it is not automatically subject to certain liability provisions and is not incorporated into other filings unless specifically referenced. No detailed financial figures are included in this report itself; those appear in the accompanying press release.